Additionally, new-generation drugs such as PCSK-9 inhibitors offer hope for improving the HRQoL in patients with hypercholesterolemia by allowing for less frequent dosing and providing a greater effectiveness [49]. Here, PCSK9 is linked to familial hypercholesterolemia.